25 min
Suresh Ramalingam MD, FACP, FASCO | Lung Cancer Staging, Targeted Therapies, Side Effects & Clinical Trials PrecisCa Oncology Podcast : Precision Cancer Insights
-
- Medicine
On this episode, PrecisCa speaks with Dr. Suresh Ramalingam, medical oncologist and Executive Director at the Winship Cancer Institute of Emory University in Atlanta, Georgia.
Dr. Ramalingam sits down with us to answer the following questions:
What is the prognosis of lung cancer by stage?
What are the side effects of targeted therapy for lung cancer & how do you manage them?
Do you ever use immunotherapy in patients with driver mutations? What are the concerns about sequencing of immunotherapy and targeted agents?
How do you treat metastatic EGFR mutated lung cancer in First, Second and Third line settings?
How do you approach brain metastases in EGFR-mutated lung cancer? What are the modalities that can be used to treat brain metastases and how do the different TKI's compare in terms of brain metastases?
What are the benefits of enrolling in a clinical trial?
Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer.Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar.Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.
Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos.
New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.
On this episode, PrecisCa speaks with Dr. Suresh Ramalingam, medical oncologist and Executive Director at the Winship Cancer Institute of Emory University in Atlanta, Georgia.
Dr. Ramalingam sits down with us to answer the following questions:
What is the prognosis of lung cancer by stage?
What are the side effects of targeted therapy for lung cancer & how do you manage them?
Do you ever use immunotherapy in patients with driver mutations? What are the concerns about sequencing of immunotherapy and targeted agents?
How do you treat metastatic EGFR mutated lung cancer in First, Second and Third line settings?
How do you approach brain metastases in EGFR-mutated lung cancer? What are the modalities that can be used to treat brain metastases and how do the different TKI's compare in terms of brain metastases?
What are the benefits of enrolling in a clinical trial?
Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer.Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar.Dr. Ramalingam holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, and International Association of Lung Cancer Study. He plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.
Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos.
New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.
25 min